Clinical impact of different exosomes’ protein expression in pancreatic ductal carcinoma patients treated with standard first line palliative chemotherapy

摘要: Introduction Pancreatic ductal adenocarcinoma is associated to dismal prognosis despite the use of palliative chemotherapy, partly due lack knowledge biological processes underlying disease progression. Exosomes have been identified as biomarkers sources in different cancer types. Aim study was analyse contents circulating exosomes patients with pancreatic who received chemotherapy. Patients and methods were submitted blood sample collection before chemotherapy (T0) after 3 months (T3). We quantified by an ELISA-based technique specific proteins cancer-derived (CD44,CD44v6,EpCAM,CD9,CD81,Tspan8,Integrin α6,Integrin β4,CD24,CXCR4). correlated baseline levels these factors changes between T3 T0 survival outcomes. Survival analyses performed Kaplan-Meier method. Correlation assessed log-rank test level statistical significance set at 0.05. Multivariate analysis logistic regression analysis. Results Nineteen enrolled. EpCAM increased from those mostly differences survival. having higher had median progression free (PFS) 3.18vs7.31 (HR:2.82,95%CI:1.03–7.73,p = 0.01). Overall (OS) shorter for (5.83vs16.45 months,HR:6.16,95%CI:1.93–19.58,p 0.0001) also response rates (RR) worse (20%vs87%,p 0.015). increase during treatment better PFS (2.88vs7.31 months,HR:0.24,95%CI:0.04–1.22,p 0.003). OS (8.75vs11.04 months, HR:0.77,95%CI:0.21–2.73,p 0.66) RR 60%vs20% (p 0.28). Among clinical that might determine on OS, only ECOG PS significantly 0.0137and<0.001 respectively).Multivariate confirmed T0/T3 independent prognostic PFS. Conclusions express EpCAM, whose change treatment. This represents a useful factor suggests future modalities target should be tested selected exosome expression.